Published by Iain Gilbert on 22nd October 2026
(Sharecast News) - Drugmaker Astrazeneca's rare‑disease unit Alexion said on Thursday that Ultomiris had won accelerated US approval as the first treatment aimed at reducing protein levels in the urine of adults with primary IgA nephropathy.
URL: http://www.digitallook.com/dl/news/story/36298622/...